World Leaders and Industry Icons Unite Under BRIDGE Alliance to Empower the Future of Media, Entertainment and Content
12.11.2025 14:11:00 CET | Business Wire | Press release
A new international alliance of policymakers, creative leaders, and innovators has come together under the banner of BRIDGE Alliance to advance inclusivity, investment, and sustainable development in the global media, entertainment and content economy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112707768/en/

World leaders and industry icons unite under BRIDGE Alliance to empower the future of media, entertainment and content (Photo: AETOSWire)
Headquartered in the UAE, BRIDGE Alliance stands as a first-of-its-kind global body chaired by H.E. Abdulla bin Mohammed bin Butti Al Hamed. It brings together an influential board comprising former heads of state, global leaders, policymakers, and CEOs from the media, communication, technology, finance, and creative sectors.
The founding board includes HRH Princess Lamia bint Majed Al Saud, CEO of Rotana Media Group and Secretary-General of Alwaleed Philanthropies; H.E. Macky Sall, fourth President of Senegal; H.E. Dr. Jamal Mohammed Obaid Al Kaabi, Vice-Chairman of BRIDGE Alliance; Jessica Sibley, CEO of TIME; Janet Yang, former President of the Academy of Motion Picture Arts and Sciences; Dr. Julie Gichuru, CEO of the Africa Leadership and Dialogue Institute; Daniil Shuleyko, CEO of Yango Group; Sanford Climan, Founder of Entertainment Media Ventures; strategist Richard Attias; and Maryam bin Fahad, Managing Director of BRIDGE Alliance.
Operating as an independent, mission-driven organization, BRIDGE Alliance reinvests all operational surpluses into advancing research, capacity building, and innovation. It aims to enhance cooperation, enabling ideas, capital, and talent to move more effectively across target sectors.
H.E. Al Hamed described the Alliance as “a humanitarian and economic project born in the UAE to redefine the relationship between media, society, and the economy — building bridges of understanding, impact, and growth among nations.” He added that BRIDGE “embodies a global ecosystem founded on collaboration, innovation, and shared responsibility, where expertise turns ideas into impact and partnerships into progress.”
The Alliance’s first major initiative, BRIDGE Summit 2025, will take place from December 8–10 at the Abu Dhabi National Exhibition Center (ADNEC). The world’s largest debut media event, it will convene 60,000 participants, 400 speakers, and 300 exhibitors across seven tracks — Media, Creator Economy, Music, Gaming, Technology, Marketing, and Picture — turning dialogue into action and expanding access to the global content economy.
From its base in the UAE, BRIDGE Alliance is a global hub for innovation, collaboration, and responsible media growth — reinforcing the nation’s role as a meeting point for ideas, creativity, and shared progress.
Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20251112707768/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom